<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04456855</url>
  </required_header>
  <id_info>
    <org_study_id>SYSEC-KY-2018-018</org_study_id>
    <nct_id>NCT04456855</nct_id>
  </id_info>
  <brief_title>Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients</brief_title>
  <acronym>SYSBTC-001</acronym>
  <official_title>Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Foshan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current guidelines lack definitive evidences about the relative benefits of locoregional
      surgery for the primary tumor in de novo stage IV breast cancer. The aim of this study
      (SYSBTC-001) was to investigate the role of locoregional surgery for primary tumor in de novo
      stage IV breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>The association between locoregional surgery and overall survival (OS), which defined as the time from the beginning of diagnosis of breast cancer to the death with any causes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Locoregional progression free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Defined as time between the time of diagnosis and the time of locoregional recurrence, or death occurred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant progression free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Distant disease free survival (D-DFS), which defined as the time from the diagnosis of de novo stage IV breast cancer to the confirmed time of distant progression, or death due to any other cause.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">358</enrollment>
  <condition>Breast Neoplasm Female</condition>
  <condition>Surgery</condition>
  <condition>Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Locoregional surgery</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>No surgery</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Locoregional surgery</intervention_name>
    <description>Patients had pathologically confirmed operable stage IV breast infiltrating carcinoma at initial presentation, and had locoregional surgery for the breast cancer.</description>
    <arm_group_label>Locoregional surgery</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Operable stage IV breast cancer patients, whose primary lesion is invasive breast cancer
        confirmed by pathology, and metastases can be confirmed by pathology or imaginology
        examination
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Operable stage IV breast cancer patients,whose primary lesion is invasive breast
             cancer confirmed by pathology, and metastases can be confirmed by pathology or
             imageology examination.

          -  ECOG-PS 0-2.

          -  Bone marrow, liver and kidney should be fully functional.

          -  Patients received the locoregional surgery of the primary tumor in de novo in our
             center, or didn't received the locoregional surgery of the primary tumor in de novo.

          -  For the patient who accepted systematic treatment before operation, the systematic
             treatment must be administered within a year since diagnosed.

        Exclusion Criteria:

          -  Accompanied with other primary malignant tumors.

          -  Patients who can't plan for follow-up effectively and regularly.

          -  Multiple liver metastasis and ALT/AST four times higher than normal at patients' first
             diagnosis.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herui Yao, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jun Tang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guolin Ye, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First People's Hospital of Foshan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Herui Yao, PhD</last_name>
    <phone>+8613500018020</phone>
    <email>yaoherui@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yunfang Yu, MD</last_name>
    <phone>+8613660238987</phone>
    <email>yuyf9@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First People's Hospital of Foshan</name>
      <address>
        <city>Foshan</city>
        <state>Guangdong</state>
        <zip>528000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guolin Ye, PhD</last_name>
      <email>13902816950@139.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hospital of Sun Yat-sen</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herui Yao, PhD</last_name>
      <phone>+8613500018020</phone>
      <email>yaoherui@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Tang, PhD</last_name>
      <email>tangjun@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 1, 2020</study_first_submitted>
  <study_first_submitted_qc>July 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Herui Yao</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Breast Neoplasm Female</keyword>
  <keyword>Locoregional surgery</keyword>
  <keyword>In de novo stage IV brest cancer</keyword>
  <keyword>Overall survival</keyword>
  <keyword>Locoregional progression free survival</keyword>
  <keyword>Distant progression free survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

